Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. - Doi, T; Takiuchi, H; Ohtsu, A; Fuse, N; Goto, M; Yoshida, M; Dote, N; Kuze, Y; Jinno, F; Fujimoto, M; Takubo, T; Nakayama, N; et al. (British Journal of Cancer, 2012)